Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-01-27
2008-10-28
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C536S023530, C435S320100, C435S328000
Reexamination Certificate
active
07442775
ABSTRACT:
The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5440021 (1995-08-01), Chuntharapai et al.
patent: 5543503 (1996-08-01), Chuntharapai et al.
patent: 5571713 (1996-11-01), Lyle et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5657277 (1997-08-01), Shirley
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5707815 (1998-01-01), Charo et al.
patent: 5808960 (1998-09-01), McClure
patent: 5859205 (1999-01-01), Adair et al.
patent: 5985279 (1999-11-01), Waldmann et al.
patent: 6006339 (1999-12-01), McClure
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6084075 (2000-07-01), Lind et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6312689 (2001-11-01), LaRosa
patent: 6352832 (2002-03-01), LaRosa et al.
patent: 6395497 (2002-05-01), LaRosa
patent: 6406694 (2002-06-01), LaRosa
patent: 6406865 (2002-06-01), LaRosa
patent: 6448021 (2002-09-01), LaRosa
patent: 6451522 (2002-09-01), LaRosa
patent: 6458353 (2002-10-01), LaRosa
patent: 6491915 (2002-12-01), LaRosa
patent: 6696550 (2004-02-01), LaRosa et al.
patent: 6727349 (2004-04-01), LaRosa et al.
patent: 7053202 (2006-05-01), O'Keefe et al.
patent: 7115379 (2006-10-01), Hardiman et al.
patent: 2003/0165494 (2003-09-01), LaRosa et al.
patent: 2004/0126851 (2004-07-01), LaRosa et al.
patent: 2004/0151721 (2004-08-01), O'Keefe et al.
patent: 2004/0265303 (2004-12-01), LaRosa et al.
patent: 2006/0147445 (2006-07-01), O'Keefe et al.
patent: WO 91/09967 (1991-07-01), None
patent: WO 94/09128 (1994-04-01), None
patent: WO 94/12214 (1994-06-01), None
patent: WO 95/08576 (1995-03-01), None
patent: WO 95/19436 (1995-07-01), None
patent: WO 97/31949 (1997-09-01), None
patent: WO 97/47319 (1997-12-01), None
patent: WO 98/42360 (1998-10-01), None
patent: WO 98/44953 (1998-10-01), None
patent: WO 99/15666 (1999-04-01), None
patent: WO 00/05265 (2000-02-01), None
Houdebine et al. Production of pharmaceutical proteins from transgenic animals, Journal of Biotechnology, 1994, 34:269-287.
Verma et al. Gene therapy—promises, problems and prospects, Nature, 1997, 389:239-242.
Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995, available from: http://www.nih.gov
ews/panelrep.html.
Li et al. Biochemistry 2000. vol. 39, p. 6296-6309.
Förster, R. et al., “A general method for screening mAbs specific for G-protein coupled receptors as exemplified by using epitope tagged BLR1-transfected 293 cells and solid-phase cell ELISA”,Biochemical and Biophysical Research Communications196(3):1496-1503 (1993).
Boring, L. et al., “Decreased lesion formation in CCR2- /-mice reveals a role for chemokines in the initiation of atherosclerosis,”Nature 394(27):894-897 (1998).
Ylä-Herttuala, S. et al., “Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions,”Proc. Natl. Acad. Sci., USA 88:5252-5256 (1991).
Taubman, M.B. et al., “JEmRNA Accumulates Rapidly in Aortic Injury and in Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cells,”Circulation Research 70(2):314-325 (1992).
Feng, A. et al., “Red Wine Inhibits Monocyte Chemotactic Protein-1 Expression and Modestly Reduces Neointimal Hyperplasia After Balloon Injury in Cholesterol-Fed Rabbits,”Circulation100:2254-2259 (1999).
Lukacs, N.W. et al., “Production of Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1 α by Inflammatory Granuloma Fibroblasts,”American Journal of Pathology144(4):711-718 (1994).
Koch, A.E., et al., “Enhanced Production of Monocyte Chemoattractant Protein-1 in Rheumatoid Arthritis,”The Jour. of Clin. Invest.90:772-779 (1992).
Harigai, M. et al., “Monocyte Chemoattractant Protein-1 (MCP-1) in Inflammatory Joint Diseases and Its Involvement in the Cytokine Network of Rheumatoid Synovium,”Clin. Immun. and Immunopathology69(1):83-91 (1993).
Villiger, P.M. et al., “Production of Monocyte Chemoattractant Protein-1 by Inflamed Synovial Tissue and Cultured Synoviocytes,”J. Immunol. 149(2):722-727 (1992).
Reinecker, H.C. et al., “Monocyte-Chemoattractant Protein 1 Gene Expression in Intestinal Epithelial Cells and Inflammatory Bowel Disease Mucosa,”Gastroenterology108(1):40-50 (1995).
Nelken, N.A. et al., “Monocyte Chemoattractant Protein-1 in Human Atheromatous Plaques,”J. Clin. Invest. 88:1121-1127 (1991).
Grewal, I.S. et al., “Transgenic Monocyte Chemoattractant Protein-1 (MCP-1) in Pancreatic Islets Produces Monocyte-Rich Insulitis Without Diabetes,”J. Immunol. 159:401-408 (1997).
Yu, X. et al., “Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates,”Proc. Natl. Acad. Sci., USA 89:6953-6957 (1992).
Berman, J.W. et al., “Localization of Monocyte Chemoattractant Peptide-1 Expression in the Central Nervous System in Experimental Autoimmune Encephalomyelitis and Trauma in the Rat,”J. Immunol. 156:3017-3023 (1996).
Lukacs, N.W. et al., “The Production of Chemotactic Cytokines an Allogeneic Response,”Amer. Jour. of Pathology143(4):1179-1188 (1993).
Christensen, P.J. et al., “Characterization of the Production of Monocyte Chemoattractant Protein-1 and IL-8 in an Allogeneic Immune Response,”The Journal of Immunology151(3):1205-1213 (1993).
Rand, M.L. et al., “Inhibition of T Cell Recruitment and Cutaneous Delayed-Type Hypersensitivity-Induced Inflammation with Antibodies to Monocyte Chemoattractant Protein-1,”Amer. Jour. of Pathology, 148(3):855-864 (1996).
Jones, M.L. and Warren, J.S., “Monocyte Chemoattractant Protein 1 in a Rat Model of Pulmonary Granulomatosis,”Laboratory Investigation66(4):498-503 (1992).
Lloyd, C.M. et al., “Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis,”Journal of Leukocyte Biology62:676-680 (1997).
Flory, C.M. et al., “Pulmonary Granuloma Formation in the Rat is Partially Dependent on Monocyte Chemoattractant Protein 1,”Laboratory Invest., 69(4):396-404 (1993).
Jones, M.L. et al., “Potential Role of Monocyte Chemoattractant Protein 1/JE In Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat,”J. Immunol.149(6):2147-2154 (1992).
Gu, L. et al., “Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice,” Molecular Cell, 2(2):275-281 (1998).
Tesch, G.H., et al., “Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis,”J. Clin. Invest. 103(1):73-80 (1999).
Lu, B., et al., “Abnormalities in Monocyte Recruitment and Cytokine Expression in Monocyte Chemoattractant Protein 1-deficient Mice,”J. Exp. Med. 187(4):601-608 (1998).
Rutledge, B.J. et al., “High Level Monocyte Chemoattractant Protein-1 Expression in Transgenic Mice Increases Their Susceptibility to Intracellular Pathogens,”J. Immunol. 155:4838-4843 (1995).
Gunn, M.D. et al., “Monocyte Chemoattractant Protein-1 Is Sufficient for the Chemotaxis of Monocytes and Lymphocytes in Transgenic Mice but Requires an Additional Stimulus for Inflammatory Activation,”J. Immunol. 158:376-383 (1997).
Chensue, S.W. et al., &#x
Horvath Christopher
Jones S. Tarran
LaRosa Gregory J.
Newman Walter
O'Brien Siobhan H.
Boesen Agnieszka
Campell Bruce
Lowrie Lando & Anastasi, LLP
Millennium Pharmaceuticals Inc.
LandOfFree
Humanized anti-CCR2 antibodies and methods of use therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-CCR2 antibodies and methods of use therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-CCR2 antibodies and methods of use therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3997292